Table 1.
Clinical characteristics by molecular subtypes.
| Characteristics | N (%) | HR-HER2-(N (%)) | HR-HER2+ (N (%)) | HR+HER2+ (N (%)) | HR+HER2-(N (%)) | Chi square | P |
|---|---|---|---|---|---|---|---|
| Year of diagnosis | 13.242 | 0.004 | |||||
| 2010–2013 | 3,517 (62.5) | 214 (71.6) | 296 (59.4) | 687 (63.3) | 2,320 (61.9) | ||
| 2014–2017 | 2,111 (37.5) | 85 (28.4) | 202 (40.6) | 399 (36.7) | 1,425 (38.1) | ||
| Age, years | 37.427 | <0.001 | |||||
| ≤60 | 2,805 (49.8) | 124 (41.5) | 254 (51.0) | 623 (57.4) | 1,804 (48.2) | ||
| >60 | 2,823 (50.2) | 175 (58.5) | 244 (49.0) | 463 (42.6) | 1,941 (51.8) | ||
| Race | 26.536 | <0.001 | |||||
| African American | 789 (14.0) | 56 (18.7) | 41 (8.2) | 135 (12.4) | 557 (14.9) | ||
| Caucasian | 4,404 (78.3) | 220 (73.6) | 420 (84.3) | 876 (80.7) | 2,888 (77.1) | ||
| Other | 435 (7.7) | 23 (7.7) | 37 (7.4) | 75 (6.9) | 300 (8.0) | ||
| Tumor size, mm | 71.106 | <0.001 | |||||
| <16 | 3,918 (69.6) | 185 (61.9) | 281 (56.4) | 732 (67.4) | 2,720 (72.6) | ||
| 16–40 | 1,377 (24.5) | 98 (32.8) | 172 (34.5) | 284 (26.2) | 823 (22.0) | ||
| >41 | 333 (5.9) | 16 (5.4) | 45 (9.0) | 70 (6.4) | 202 (5.4) | ||
| Grade | 1,093.189 | <0.001 | |||||
| Low | 964 (17.1) | 11 (3.7) | 6 (1.2) | 67 (6.2) | 880 (23.5) | ||
| Intermediate | 2,304 (40.9) | 63 (21.1) | 54 (10.8) | 356 (32.8) | 1,831 (48.9) | ||
| High | 2,360 (41.9) | 225 (75.3) | 438 (88.0) | 663 (61.0) | 1,034 (27.6) | ||
| Histology Subtype | 322.407 | <0.001 | |||||
| Intraductal, solid | 2,240 (39.8) | 128 (42.8) | 221 (44.4) | 484 (44.6) | 1,407 (37.6) | ||
| Comedo necrosis | 599 (10.6) | 73 (24.4) | 121 (24.3) | 142 (13.1) | 263 (7.0) | ||
| Cribriform | 525 (9.3) | 9 (3.0) | 16 (3.2) | 58 (5.3) | 442 (11.8) | ||
| Other | 2,264 (40.2) | 89 (29.8) | 140 (28.1) | 402 (37.0) | 1,633 (43.6) | ||
| Radiotherapy | 47.361 | <0.001 | |||||
| Yes | 4,040 (71.8) | 243 (81.3) | 390 (78.3) | 824 (75.9) | 2,583 (69.0) | ||
| No | 1,588 (28.2) | 56 (18.7) | 108 (21.7) | 262 (24.1) | 1,162 (31.0) | ||
| Prognostic Score* | 426.311 | <0.001 | |||||
| Low risk | 3,549 (63.1) | 142 (47.5) | 171 (34.3) | 536 (49.4) | 2,700 (72.1) | ||
| High risk | 2,079 (36.9) | 157 (52.5) | 327 (65.7) | 550 (50.6) | 1,045 (27.9) | ||
Abbreviations: N, numbers; HR, hormone receptor; HER2, human epidermal growth factor receptor-2.
Note: * Prognostic score is a scoring method by age, tumor size, and grade to stratify DCIS patients into low-risk and high-risk group.